These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8992022)

  • 21. Parent drug and/or metabolite? Which of them is most appropriate to establish bioequivalence of two oral oxcarbazepine formulations in healthy volunteers?
    Di Girolamo G; Opezzo JA; Schere D; Gonzalez CD; Moncalvo JJ
    Expert Opin Pharmacother; 2007 Jul; 8(10):1415-23. PubMed ID: 17661724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment.
    Friis ML; Kristensen O; Boas J; Dalby M; Deth SH; Gram L; Mikkelsen M; Pedersen B; Sabers A; Worm-Petersen J
    Acta Neurol Scand; 1993 Mar; 87(3):224-7. PubMed ID: 8475694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxcarbazepine.
    Beydoun A; Kutluay E
    Expert Opin Pharmacother; 2002 Jan; 3(1):59-71. PubMed ID: 11772334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans.
    Almeida L; Soares-da-Silva P
    Drugs R D; 2003; 4(5):269-84. PubMed ID: 12952496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine.
    Rosaria Muscatello M; Pacetti M; Cacciola M; La Torre D; Zoccali R; D'Arrigo C; Migliardi G; Spina E
    Epilepsia; 2005 May; 46(5):771-4. PubMed ID: 15857446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Further clinical and pharmacokinetic observations on the new anticonvulsant, oxcarbazepine.
    Dickinson RG; Hooper WD; Pendlebury SC; Moses D; Eadie MJ
    Clin Exp Neurol; 1988; 25():127-33. PubMed ID: 3077098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative stereoselective pharmacokinetic analysis of 10-hydroxycarbazepine after oral administration of its individual enantiomers and the racemic mixture to dogs.
    Volosov A; Yagen B; Bialer M
    Epilepsia; 2000 Sep; 41(9):1107-11. PubMed ID: 10999549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy.
    Pisani F; Fazio A; Oteri G; Artesi C; Xiao B; Perucca E; Di Perri R
    Acta Neurol Scand; 1994 Aug; 90(2):130-2. PubMed ID: 7801739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma concentration of topiramate correlates with cerebrospinal fluid concentration.
    Christensen J; Højskov CS; Dam M; Poulsen JH
    Ther Drug Monit; 2001 Oct; 23(5):529-35. PubMed ID: 11591899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy.
    Yu Y; Zhang Q; Xu W; Lv C; Hao G
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):345-51. PubMed ID: 25700977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal) on a named-patient basis.
    Van Parys JA; Meinardi H
    Epilepsy Res; 1994 Sep; 19(1):79-85. PubMed ID: 7813417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hippocampal dopamine and serotonin elevations as pharmacodynamic markers for the anticonvulsant efficacy of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine.
    Clinckers R; Smolders I; Meurs A; Ebinger G; Michotte Y
    Neurosci Lett; 2005 Dec; 390(1):48-53. PubMed ID: 16139430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxcarbazepine and spasticity: further observations.
    Bittencourt PR
    Arq Neuropsiquiatr; 1988 Dec; 46(4):382-4. PubMed ID: 3072937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers.
    Nunes T; Rocha JF; Falcão A; Almeida L; Soares-da-Silva P
    Epilepsia; 2013 Jan; 54(1):108-16. PubMed ID: 22812691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine.
    Sigaroudi A; Kullak-Ublick GA; Weiler S
    Eur J Clin Pharmacol; 2016 Mar; 72(3):377-8. PubMed ID: 26631062
    [No Abstract]   [Full Text] [Related]  

  • 36. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine.
    van Heiningen PN; Eve MD; Oosterhuis B; Jonkman JH; de Bruin H; Hulsman JA; Richens A; Jensen PK
    Clin Pharmacol Ther; 1991 Oct; 50(4):410-9. PubMed ID: 1914377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024.
    Ambrósio AF; Soares-Da-Silva P; Carvalho CM; Carvalho AP
    Neurochem Res; 2002 Feb; 27(1-2):121-30. PubMed ID: 11926264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A simple method to monitor plasma concentrations of oxcarbazepine, carbamazepine, their main metabolites and lamotrigine in epileptic patients.
    Franceschi L; Furlanut M
    Pharmacol Res; 2005 Apr; 51(4):297-302. PubMed ID: 15683742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of carbamazepine in the dog.
    Frey HH; Löscher W
    Arch Int Pharmacodyn Ther; 1980 Feb; 243(2):180-91. PubMed ID: 7377892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance.
    Baruzzi A; Albani F; Riva R
    Epilepsia; 1994; 35 Suppl 3():S14-9. PubMed ID: 8156974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.